BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals Statistics

Total Valuation

BCRX has a market cap or net worth of $1.64 billion. The enterprise value is $2.15 billion.

Market Cap	1.64B
Enterprise Value	2.15B

Important Dates

The next estimated earnings date is Monday, February 24, 2025, before market open.

Earnings Date	Feb 24, 2025
Ex-Dividend Date	n/a

Share Statistics

BCRX has 207.13 million shares outstanding. The number of shares has increased by 8.84% in one year.

Current Share Class	207.13M
Shares Outstanding	207.13M
Shares Change (YoY)	+8.84%
Shares Change (QoQ)	+0.23%
Owned by Insiders (%)	0.97%
Owned by Institutions (%)	78.27%
Float	193.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.93
Forward PS	3.01
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	5.21
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.78

Current Ratio	2.78
Quick Ratio	2.62
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.35

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-4.25%
Return on Invested Capital (ROIC)	-5.34%
Return on Capital Employed (ROCE)	-10.22%
Revenue Per Employee	$769,737
Profits Per Employee	-$231,002
Employee Count	536
Asset Turnover	0.81
Inventory Turnover	10.62

Taxes

Income Tax	-308,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +43.64% in the last 52 weeks. The beta is 1.76, so BCRX's price volatility has been higher than the market average.

Beta (5Y)	1.76
52-Week Price Change	+43.64%
50-Day Moving Average	7.60
200-Day Moving Average	7.11
Relative Strength Index (RSI)	54.44
Average Volume (20 Days)	2,475,678

Short Selling Information

The latest short interest is 17.01 million, so 8.21% of the outstanding shares have been sold short.

Short Interest	17.01M
Short Previous Month	15.72M
Short % of Shares Out	8.21%
Short % of Float	8.80%
Short Ratio (days to cover)	7.86

Income Statement

In the last 12 months, BCRX had revenue of $412.58 million and -$123.82 million in losses. Loss per share was -$0.60.

Revenue	412.58M
Gross Profit	215.11M
Operating Income	-34.51M
Pretax Income	-146.50M
Net Income	-123.82M
EBITDA	-31.94M
EBIT	-34.51M
Loss Per Share	-$0.60

Balance Sheet

The company has $330.01 million in cash and $842.14 million in debt, giving a net cash position of -$512.13 million or -$2.47 per share.

Cash & Cash Equivalents	330.01M
Total Debt	842.14M
Net Cash	-512.13M
Net Cash Per Share	-$2.47
Equity (Book Value)	-468.56M
Book Value Per Share	-2.26
Working Capital	273.56M

Cash Flow

In the last 12 months, operating cash flow was -$55.73 million and capital expenditures -$1.00 million, giving a free cash flow of -$56.73 million.

Operating Cash Flow	-55.73M
Capital Expenditures	-1.00M
Free Cash Flow	-56.73M
FCF Per Share	-$0.27

Margins

Gross margin is 52.14%, with operating and profit margins of -8.37% and -30.01%.

Gross Margin	52.14%
Operating Margin	-8.37%
Pretax Margin	-30.09%
Profit Margin	-30.01%
EBITDA Margin	-7.74%
EBIT Margin	-8.37%
FCF Margin	n/a

Dividends & Yields

BCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.84%
Shareholder Yield	-8.84%
Earnings Yield	-7.57%
FCF Yield	-3.47%

Analyst Forecast

The average price target for BCRX is $15.50, which is 96.20% higher than the current price. The consensus rating is "Buy".

Price Target	$15.50
Price Target Difference	96.20%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	18.31%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BCRX has an Altman Z-Score of -2.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.91
Piotroski F-Score	4